Anti-metastatic effect of cantharidin in A549 human lung cancer cells

[1]  Xin-en Huang,et al.  Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[2]  Y. Miao,et al.  Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress‐independent growth inhibition of pancreatic cancer cells through G2/M cell‐cycle arrest and apoptosis , 2010, Cancer science.

[3]  H. Liao,et al.  A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. , 2009, Chemico-biological interactions.

[4]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[5]  T. Salo,et al.  Tumor microenvironment and angiogenesis. , 2008, Frontiers in bioscience : a journal and virtual library.

[6]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[7]  H. Um,et al.  Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. , 2006, Cancer research.

[8]  A. Chan,et al.  Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. , 2006, International journal of molecular medicine.

[9]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[10]  H. Duc,et al.  In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. , 2005, Basic & clinical pharmacology & toxicology.

[11]  D. Hu,et al.  Uveal melanocytes produce matrix metalloproteinases-2 and -9 in vitro. , 2004, Pigment cell research.

[12]  Ken Jacobson,et al.  MAP kinases and cell migration , 2004, Journal of Cell Science.

[13]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[14]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[15]  A. Weeraratna,et al.  Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. , 2000, Cancer research.

[16]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  K. Almholt,et al.  Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. , 1998, Current opinion in cell biology.

[19]  P. Basset,et al.  Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[20]  H. Sato,et al.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. , 1993, Oncogene.